Bausch + Lomb Corp
BLCO15.190USD
-0.190-1.24%
Cierre 09/19, 16:00（ET）Cotizaciones retrasadas 15 min
5.37BCap. mercado
PérdidaP/E TTM
Más Datos de Bausch + Lomb Corp Compañía
Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.
Información de la empresa
Símbolo de cotizaciónBLCO
Nombre de la empresaBausch + Lomb Corp
Fecha de salida a bolsaMay 06, 2022
Director ejecutivoMr. Brenton L. (Brent) Saunders, J.D.
Número de empleados13500
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 06
Dirección520 Applewood Crescent
CiudadVAUGHAN
Bolsa de valoresNYSE Consolidated
PaísCanada
Código postalL4K 4B4
Teléfono19082552864
Sitio Webhttps://ir.bausch.com/
Símbolo de cotizaciónBLCO
Fecha de salida a bolsaMay 06, 2022
Director ejecutivoMr. Brenton L. (Brent) Saunders, J.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
64.91K
+53.22%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
Ms. Sarah B. Kavanagh
Ms. Sarah B. Kavanagh
Independent Director
Independent Director
--
--
Mrs. Nathalie Bernier
Mrs. Nathalie Bernier
Independent Director
Independent Director
--
--
Mr. Andrew J. Stewart
Mr. Andrew J. Stewart
President - Global Pharmaceuticals and International Consumer
President - Global Pharmaceuticals and International Consumer
--
--
Mr. Sam A. Eldessouky
Mr. Sam A. Eldessouky
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brenton L. (Brent) Saunders, J.D.
Mr. Brenton L. (Brent) Saunders, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
352.13K
+162.32%
Mr. Luc Bonnefoy
Mr. Luc Bonnefoy
President - Surgical
President - Surgical
77.36K
+8.63%
Dr. Yehia Hashad, M.D.
Dr. Yehia Hashad, M.D.
Executive Vice President - Research & Development, Chief Medical Officer
Executive Vice President - Research & Development, Chief Medical Officer
68.18K
+35.10%
Mr. Russel C. Robertson
Mr. Russel C. Robertson
Independent Director
Independent Director
64.91K
+53.22%
Dr. Andrew Charles Von Eschenbach, M.D.
Dr. Andrew Charles Von Eschenbach, M.D.
Independent Director
Independent Director
62.09K
+55.01%
Mr. A. Robert D. Bailey, J.D.
Mr. A. Robert D. Bailey, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
--
--
Desglose de ingresos
Divisa: USDActualizado: dom., 6 de jul
Divisa: USDActualizado: dom., 6 de jul
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Devices
448.00M
39.40%
OTC
409.00M
35.97%
Pharmaceuticals
222.00M
19.53%
Branded and other Generics
54.00M
4.75%
Other revenues
4.00M
0.35%
Sin datos
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Devices
448.00M
39.40%
OTC
409.00M
35.97%
Pharmaceuticals
222.00M
19.53%
Branded and other Generics
54.00M
4.75%
Other revenues
4.00M
0.35%
Estadísticas de accionistas
Actualizado: lun., 18 de ago
Actualizado: lun., 18 de ago
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Bausch Health Companies Inc
87.69%
Icahn Associates Corporation
0.99%
Deutsche Bank Securities Inc.
0.96%
Alberta Investment Management Corporation
0.92%
D. E. Shaw & Co., L.P.
0.74%
Otro
8.70%
Accionistas
Accionistas
Proporción
Bausch Health Companies Inc
87.69%
Icahn Associates Corporation
0.99%
Deutsche Bank Securities Inc.
0.96%
Alberta Investment Management Corporation
0.92%
D. E. Shaw & Co., L.P.
0.74%
Otro
8.70%
Tipos de accionistas
Accionistas
Proporción
Corporation
87.70%
Hedge Fund
3.49%
Investment Advisor/Hedge Fund
3.32%
Research Firm
1.54%
Investment Advisor
1.53%
Sovereign Wealth Fund
0.92%
Individual Investor
0.48%
Pension Fund
0.25%
Family Office
0.24%
Otro
0.54%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
263
350.71M
99.08%
-19.09M
2025Q1
273
350.60M
99.12%
-19.40M
2024Q4
262
347.48M
98.58%
-23.77M
2024Q3
257
349.38M
99.14%
-19.72M
2024Q2
260
352.10M
99.92%
-21.43M
2024Q1
247
349.79M
99.91%
-25.18M
2023Q4
237
351.31M
100.35%
-21.66M
2023Q3
219
355.43M
101.52%
-16.80M
2023Q2
207
357.28M
102.06%
-12.23M
2023Q1
194
356.91M
101.97%
-11.11M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Bausch Health Companies Inc
310.45M
87.77%
--
--
Mar 24, 2025
Icahn Associates Corporation
3.50M
0.99%
--
--
Mar 31, 2025
Deutsche Bank Securities Inc.
3.50M
0.99%
+3.50M
--
Mar 31, 2025
Alberta Investment Management Corporation
3.27M
0.92%
+258.00K
+8.58%
Mar 31, 2025
D. E. Shaw & Co., L.P.
1.88M
0.53%
-6.18K
-0.33%
Mar 31, 2025
GoldenTree Asset Management, LP
2.25M
0.64%
+516.07K
+29.79%
Mar 31, 2025
Whitebox Advisors, L.L.C.
1.62M
0.46%
+179.78K
+12.46%
Mar 31, 2025
Nomura Securities Co., Ltd.
1.26M
0.36%
--
--
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 6 de sep
Actualizado: sáb., 6 de sep
Nombre
Proporción
Invesco RAFI Developed Mkts ex-US SM ETF
0%
Schwab Fundamental International Small Equity ETF
0%
BNY Mellon US Small Cap Core Equity ETF
0%
Goldman Sachs MarketBeta US 1000 Equity ETF
0%
Invesco Zacks Mid-Cap ETF
0%
First Trust US Equity Opportunities ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
Ballast Small/Mid Cap ETF
0%
Renaissance IPO ETF
0%
Invesco RAFI Developed Mkts ex-US SM ETF
Proporción0%
Schwab Fundamental International Small Equity ETF
Proporción0%
BNY Mellon US Small Cap Core Equity ETF
Proporción0%
Goldman Sachs MarketBeta US 1000 Equity ETF
Proporción0%
Invesco Zacks Mid-Cap ETF
Proporción0%
First Trust US Equity Opportunities ETF
Proporción0%
DFA Dimensional International Core Equity 2 ETF
Proporción0%
Ballast Small/Mid Cap ETF
Proporción0%
Renaissance IPO ETF
Proporción0%
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
